iTeos Therapeutics Announces $120 Million Registered Direct Offering
ITOSiTeos Therapeutics(ITOS) Newsfilter·2024-05-10 20:24
  • Led by existing investors RA Capital Management and Boxer Capital - Purchase price of 17.50representsapremiumofapproximately4417.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro forma cash position of 715 million, extending anticipated runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno ...